Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center

Ping Wu, Wei Ling, Chengwei Luo, Xiaomei Chen, Lisi Huang, Jinghua Wang, Peilong Lai, Suijing Wu, Xin Du, Jianyu Weng

Blood (2023) 142 (Supplement 1): 2890.

https://doi.org/10.1182/blood-2023-187924

Published: 2023

Journal Articles

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Lisi Huang, Suxia Geng, Yulian Wang, Zesheng Lu, Chengxin Deng, Xin Huang, Minming Li, Lingji Zeng, Qiong Luo, Peilong Lai, Xin Du, Jianyu Weng

Blood (2023) 142 (Supplement 1): 4545.

https://doi.org/10.1182/blood-2023-185222

Published: 2023

Journal Articles

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Peilong Lai, Mingyan Wu, Minming Li, Chengxin Deng, Zesheng Lu, Chenwei Luo, Xin Huang, Pengjun Liao, Lisi Huang, Ping Wu, Wang Yulian, Changchun Wan, Wei Ling, Liye Zhong, Suijing Wu, Xin Du, MD PhD, Jianyu Weng, MD

Blood (2018) 132 (Supplement 1): 5229.

https://doi.org/10.1182/blood-2018-99-116234

Published: 2018

Journal Articles

Comparison of the 5 Year Medical Outcome and Quality of Life of Patients with Chronic Myeloid Leukemia Treated with Imatinib or Allogeneic Transplant

Lisi Huang, Xin Du, Jianyu Weng, MD, Peilong Lai, Zesheng Lu, Ping Wu, Suijing Wu, PhD, Chengwei Luo, Xin Huang, Suxia Geng

Blood (2015) 126 (23): 2118.

https://doi.org/10.1182/blood.V126.23.2118.2118

Published: 2015

Journal Articles

Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia

Xiaomei Chen, Jianyu Weng, Yulian Wang, Chengxin Deng, Chengwei Luo, Pengjun Liao, Minming Li, Xin Huang, Peilong Lai, Lisi Huang, Zhi Cao, Changchun Wan, Liye Zhong, Suijing Wu, Zesheng Lu, Xiaoli Zou, Xin Du

Blood (2015) 126 (23): 4897.

https://doi.org/10.1182/blood.V126.23.4897.4897

Published: 2015

NARROW

Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Comparison of the 5 Year Medical Outcome and Quality of Life of Patients with Chronic Myeloid Leukemia Treated with Imatinib or Allogeneic Transplant

Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Chidamide-Based Pre-Emptive Treatment for High-Risk AML Patients after Hematopoietic Stem Cell Transplantation: A Real-World Experience from Chinese Single-Center

Treatment-Free Remission Era: BCR-ABL1 mRNA Transcript Level <5% at 3 Months Predicts 24-Month Deep Molecular Response and Better Survival

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Comparison of the 5 Year Medical Outcome and Quality of Life of Patients with Chronic Myeloid Leukemia Treated with Imatinib or Allogeneic Transplant

Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only